Voices
Hong Jae Chon: New Phase 2 Data Support Ivonescimab Plus Gem/Cis as First-Line Therapy for Advanced BTC
Hong Jae Chon/X

Hong Jae Chon: New Phase 2 Data Support Ivonescimab Plus Gem/Cis as First-Line Therapy for Advanced BTC

Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:

“Ivonescimab plus Gem/Cis shows strong 1L efficacy in advanced BTC.
ORR 66.7%, DCR 100%
 mOS 16.8 mo, mPFS 8.5 mo
 High MAP2K7 linked to resistance.”

Title: Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial

Authors: Qi Xu, Shurui Zhou, Chenbo Zhang, Yiwen Zhou, Yatong He, Yvchao Jiang, Jingjing Li, Tienan Yi, Cong Luo, Lei Zhang, Jia Wu, Yuhua Zhang, Minhua Wu, Qing Wei, Qi Li, Bo Liu, Xiangming Chen, Yinye Yao, Chengkun Yu, Jijuan Li, Yan Ren, Wei Zhuo, Li Yuan, Wenting Li, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Yanru Xie, Kui Wu, Jieer Ying

Read the article.

Hong Jae Chon

Read also the article about advanced BTC on OncoDaily.

TOURMALINE

 

Advanced BTC Baiyong Li Biliary tract cancer Bo Liu cancer Chenbo Zhang Chengkun Yu Cong Luo gemcitabine and cisplatin Hong Jae Chon ivonescimab Jia Wu Jie'er Ying Jijuan Li Jingjing Li Kui Wu Lei Zhang Li Yuan Michelle Xia Minhua Wu OncoDaily Oncology Qi Li Qi Xu Qing Wei Shurui Zhou Tienan Yi Wei Zhuo Wenting Li Xiangming Chen Yan Ren Yanru Xie Yatong He Yinye Yao Yiwen Zhou Yuhua Zhang Yvchao Jiang Zhongmin Maxwell Wang